SEC Form SCHEDULE 13G filed by Anebulo Pharmaceuticals Inc.

$ANEB
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ANEB alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Mangrove Partners IM, LLC
 
Signature:Nathaniel August
Name/Title:Nathaniel August, President
Date:03/17/2025
 
Nathaniel August
 
Signature:Nathaniel August
Name/Title:Nathaniel August
Date:03/17/2025
Get the next $ANEB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANEB

DatePrice TargetRatingAnalyst
More analyst ratings

$ANEB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing. FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediat

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise. In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children Anebu

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2024, and recent updates. First Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo announced it has been awarded the first tranche of a two-year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), under award number 1U01DA059995-01. With the support of NIDA, Anebulo aims to complete IND-enabling

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANEB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANEB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANEB
SEC Filings

See more

$ANEB
Leadership Updates

Live Leadership Updates

See more
  • Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

    Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer.  Ms. Gardiner joins Anebul

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANEB
Financials

Live finance-specific insights

See more
  • Ligand Reports Third Quarter 2023 Financial Results

    Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

    $AMGN
    $ANEB
    $JAZZ
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Ligand Reports First Quarter 2023 Financial Results

    2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

    $ANEB
    $LGND
    $NOVN
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

    Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of

    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care